← All trials
NCT06205485
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 26, 2024
- Primary completion
- Jan 30, 2030
- Completion date
- Jun 30, 2030
- First posted
- Jan 16, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Canadian Cancer Trials GroupLead sponsor
- National Cancer Institute (NCI)Collaborator
- NRG OncologyCollaborator
- ECOG-ACRIN Cancer Research GroupCollaborator
- SWOG Cancer Research NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.